ENB is a rare malignancy, with optimal management remaining uncertain. Our experience suggests that aggressive management seems successful in providing sustained LRC with acceptable long-term toxicity. The role of elective nodal irradiation to the upper neck remains unclear.
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Rates of symptomatic radiation necrosis appear to be higher for the BRAF inhibitor therapy group. Prospective studies investigating BRAF inhibitor therapy and SRS for melanoma brain metastases should consider incorporating methods to decrease potential radiation necrosis, including fractionating radiosurgery.
(S010) A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial—Feasibility and Acute Toxicity
This study demonstrates that even though most MRI-identified GTVs are located in close proximity to critical structures, dose escalation is achievable without exceeding rectal constraints in all cases, and bladder constraints in the majority of cases. These variations are in cases with small bladders encompassed in the CTV and are not associated with increased acute toxicity.
Targeted combinatorial therapy with XRT is necessary to overcome adaptive radioresistance. RPPA is a powerful proteomic platform, suggesting alterations in energy metabolism following XRT that are targetable by inhibition of the enzyme glutaminase. Further in vivo experiments with glutaminase inhibition and xenograft models to assess combinatorial efficacy with radiation are warranted.
(S047) Radiotherapy vs Chemotherapy Effects on Neuronal Architecture and Spine Density in the Hippocampus
Exposure to chemotherapy or RT disrupts the formation and establishment of proper synaptic connections by causing significant alterations in neuronal structure that compromise neurotransmission and cognition.
(P030) Metaplastic Breast Carcinoma at a Single Institution: Clinical-Pathologic Characteristics and Outcome
Similar to other reported series, the majority of our patients had triple-negative disease, and our patient population did not express the HER2/neu oncoprotein. Our predominant histology was squamous differentiation, whereas heterogeneity in histology is described in the literature. Despite high-grade disease, the outcomes in our study are favorable in comparison with previously reported series, although the follow-up is short.
(P045) Multimodality Therapy With Intensity-Modulated Radiotherapy for Locally Advanced Esophageal Cancer
Patients who undergo surgery after chemoradiotherapy demonstrate improved survival; however, this may be related to underlying comorbidities that preclude surgery. IMRT appears to be a reasonable treatment option that may reduce complications from radiotherapy. Careful attention should be given to heart dose during treatment planning.
(P099) Influence of Surveillance PET/CT on Detection of Early Recurrence Following Definitive Radiation in Stage III Non–Small-Cell Lung Cancer
In stage III NSCLC patients treated with definitive radiation, increased frequency of PET-CT scan surveillance did not result in decreased time to detection of locoregional or distant recurrence or improved survival. If validated, further investigation is warranted to elucidate the benefit, if any, of NSCLC posttreatment surveillance with PET-CT scan.
(P117) Outcomes, Patterns of Failures, and Toxicity for Patients Diagnosed With Pulmonary Metastases Treated With Stereotactic Body Ablative Radiotherapy (SABR)
SABR is an effective treatment modality for patients with pulmonary metastases, with excellent local control. Further studies are warranted to elucidate which patients with pulmonary metastases would benefit from the local control with SABR and determine when to treat with systemic therapy due to quick progression of distant metastases.
(P132) Evaluation of the Chest Wall Skin Dose Associated With Bolus Application in Postmastectomy Radiation Therapy (PMRT) Using Nanodot OSLD
Skin dose is dependent on patient anatomy, the incident beam geometry, and planning techniques. For example, RapidArc plans with tissue expanders should be monitored for skin dose coverage. In conclusion, the skin dose should be measured to ensure that the clinically desired dose is obtained for the various bolus applications in patients undergoing PMRT.